CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 750 target
Drug / intervention
Busulfan +26 moredrug
Likely dose
Not stated in record
Key inclusion· 14
  • Diagnosis of neuroblastoma or ganglioneuroblastoma (nodular) verified by tumor pathology or bone marrow with elevated urinary catecholamine metabolites
  • INRG stage M with MYCN amplification (>4-fold) or age >547 days
  • INRG stage MS with MYCN amplification
  • INRG stage L2 with MYCN amplification
Key exclusion· 9
  • INRG stage L2 without MYCN amplification
  • Bone marrow failure syndromes
  • Contraindication to targeted radiopharmaceutical therapy
  • Pregnant females

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03126916
NCT03126916Phase 3RecruitingHigh MomentumUpdated 4mo ago
Long Recruiting

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Children's Oncology Group·interventional·Posted Apr 25, 2017·Updated Feb 27, 2026

In Brief

A Phase 3 clinical trial evaluating Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, and 25 other interventions for Ganglioneuroblastoma and 2 related conditions. Currently recruiting, targeting 750 participants across 162 sites in 3 countries.

Signals

Enrolling ahead of pace

Detailed Summary

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Puerto Rico, United States

Timeline

Phase 3Recruiting
201720182019202020212022202320242025202620272028202920302031
First PostedApr 25, 2017
Enrollment StartMay 14, 2018
Primary CompletionSep 30, 2030
TodayJul 2, 2026
Enrollment to primary: 12.4 yearsPosted 9.2 years agoPrimary completion in 4.2 years

Interventions

Autologous Hematopoietic Stem Cell Transplantationprocedure

Undergo autologous HSCT

Biospecimen Collectionprocedure

Undergo blood sample collection

Bone Marrow Aspiration and Biopsyprocedure

Undergo bone marrow aspiration and biopsy

Busulfandrug

Given IV

Carboplatindrug

Given IV

Cisplatindrug

Given IV

Computed Tomographyprocedure

Undergo CT scan

Cyclophosphamidedrug

Given IV

Dexrazoxane Hydrochloridedrug

Given IV

Dinutuximabbiological

Given IV

Doxorubicin Hydrochloridedrug

Given IV

Echocardiography Testprocedure

Undergo echocardiography

Etoposide Phosphatedrug

Given IV

External Beam Radiation Therapyradiation

Undergo EBRT

Iobenguane I-123radiation

Given 123 I-MIBG

Iobenguane I-131radiation

Given IV

Isotretinoindrug

Given PO

Lorlatinibdrug

Given PO

Magnetic Resonance Imagingprocedure

Undergo MRI

Melphalan Hydrochloridedrug

Given IV

Multigated Acquisition Scanprocedure

Undergo MUGA scan

Positron Emission Tomographyprocedure

Undergo PET scan

Sargramostimbiological

Given SC

Therapeutic Conventional Surgeryprocedure

Undergo standard of care surgery

Thiotepadrug

Given IV

Topotecan Hydrochloridedrug

Given IV

Vincristine Sulfatedrug

Given IV